Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 324

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

ACVBP versus CHOP plus Radiotherapy for Localized Aggressive Lymphoma

Open access
Reyes, Félix, Lepage, Eric, Ganem, Gérard, Molina, Thierry J., Brice, Pauline, Coiffier, Bertrand, Morel, Pierre, Ferme, Christophe, Bosly, Andre, Lederlin, Pierre, Laurent, Guy, Tilly, Hervé·2005·New England Journal of Medicine

Abstract

BACKGROUND: Chemoradiotherapy is standard treatment for localized aggressive lymphoma. To determine the optimal therapy for nonelderly persons with low-risk localized lymphoma, we conducted a randomized trial comparing chemoradiotherapy with chemotherapy alone. METHODS: Previously untreated patients less than 61 years old with localized stage I or II aggressive lymphoma and no adverse prognostic factors according to the International Prognostic Index were randomly assigned to three cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus involved-field radiotherapy (329 patients) or chemotherapy alone with dose-intensified doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) plus sequential consolidation (318 patients). RESULTS: With a median follow-up of 7.7 years, event-free and overall survival rates were significantly higher in the group given chemotherapy alone than in the group given CHOP plus radiotherapy (P<0.001 and P=0.001, respectively). The five-year estimates of event-free survival were 82 percent (95 percent confidence interval, 78 to 87 percent) for patients receiving chemotherapy alone and 74 percent (95 percent confidence interval, 69 to 78 percent) for those receiving chemoradiotherapy. The respective five-year estimates of overall survival were 90 percent (95 percent confidence interval, 87 to 93 percent) and 81 percent (95 percent confidence interval, 77 to 86 percent). In a multivariate analysis, event-free and overall survival rates were affected by treatment group, independently of tumor stage and the presence or absence of bulky disease. CONCLUSIONS: In patients under 61 years of age, chemotherapy with three cycles of ACVBP followed by sequential consolidation is superior to three cycles of CHOP plus radiotherapy for the treatment of low-risk localized lymphoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa042040

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 324

Metadata

Authors
Reyes, F., Lepage, E., Ganem, G., Molina, T. J., Brice, P., Coiffier, B., Morel, P., Ferme, C., Bosly, A., Lederlin, P., Laurent, G., & Tilly, H.
Venue
New England Journal of Medicine
Published
2005-03-24
Volume
352
Issue
12
Pages
1197-1205
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2065157786
Cited by
324
References
19
FWCI
17.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ACVBP versus CHOP plus Radiotherapy for Localized Aggressive Lymphoma. https://app.cochat.ai/papers/10.1056/nejmoa042040
The paper
Reyes, F., Lepage, E., Ganem, G., Molina, T. J., Brice, P., Coiffier, B., Morel, P., Ferme, C., Bosly, A., Lederlin, P., Laurent, G., & Tilly, H. (2005). ACVBP versus CHOP plus Radiotherapy for Localized Aggressive Lymphoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa042040

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.